Helus Psychedelic HLP003 Hits Phase 3 Depression Goal, but Serious Adverse Events Draw Scrutiny
Helus Pharma says its deuterated psilocin beat placebo on depression scores at six and 12 weeks in a 222-patient Phase 3 trial. Three treatment-related serious adverse events, including a suicide attempt, have prompted safety questions. The data have not been peer-reviewed.